Avviso pubblico PNRR 2023
Sono stati approvati n. 6 progetti con l’Istituto come Destinatario Istituzionale.
|
Codice Locale Progetto |
Titolo |
DI |
| PNRR-POC-2023-12377318 |
Radiolabeled FPR1 Inhibitors for a Theranostic Application on Solid TumorsRITAST |
Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377998 | ValproIc acid to potentiate anti-EGFR treatment efficacy and prevent/revert resistance In colorectal cancer (VICTORIA) | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377462 |
Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma |
Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377323 |
A multimodal and multicenter approach for biobanking of biological materials and associated clinical data to improve rehabilitation in breast cancer patients with cognitive impairment |
Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377133 | Extended genomic profiling of circulating tumor DNA (ctDNA) to improve precision treatment of metastatic colorectal cancer patients | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT1-2023-12378005 | Spatial radiomIcs and tRanscriptomics to the dIscovery of the cross-link between colon cancer and chrOnic kidney disease in the SIRIO study | Istituto nazionale tumori Fondazione Giovanni Pascale |
Inoltre, n. 22 progetti sono stati approvati con l’Istituto come unità esterna partecipante.
| Codice Locale Progetto | Titolo | DI |
| PNRR-TR1-2023-12377450 | DECODING THE EXTRACELLULAR VESICLES-DRIVEN COMMUNICATION IN THE MICROENVIRONMENT OF HAIRY CELL LEUKEMIA TO IMPROVE PATIENT CARE MANAGEMENT | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12377199 | New preclinical and clinical approaches to mesothelioma, an archetypal inflammatory tumor | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377496 | Targeting therapy-induced paracrine signaling pathways in prostate cancer to prevent disease progression and resistance | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377229 | New theranostic biomarkers of Intraductal papilary mucinous neoplasm (IPMN) progression to pancreatic cancer for patients’ outcome improvement | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-POC-2023-12378165 | A PROOF OF CONCEPT CLINICAL TRIAL OF COMBINATION OF IMMUNE CHECKPOINT INHIBITION AND MICROBIOTA-DERIVED POSTBIOTIC IN TRIPLE NEGATIVE BREAST CANCER PATIENTS | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-POC-2023-12377326 | Identification of targetable vulnerabilities in redox homeostasis pathways as a novel therapeutic approach for human T-cell malignancies | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12377102 | MultiomIc aNalysis to Develop a predictive Signature plEural mesoThelioma-MINDSET | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377164 | Characterization of immune genotypes and antibody profiles to foster the discoVERY of diagnostic bioMARKERS of liver cancer development (VERYMARKERS) | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-2378166 | Preventive and prEdictive diagNostiC approaches in High-risk meLanoma: implications for hereditability and response to therapy. The PENCIL project | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-POC-2023-12377841 | Scale-up the industrial development of CD99-null exTracellular vesicles (EVs) As theRapeutic Tools by using Ewing sarcoma as prototype (START) | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12378226 | Soft Tissue Sarcoma: instrumented evaluation of motor performance and impact of Robotic Rehabilitation, Nutrition and efficacy of Nutraceuticals, and Quality of Life assessment (START-RUN) | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12377644 | PROFILES OF INTRATUMORAL MICROBIOTA IN NEUROENDOCRINE NEOPLASMS AND SOFT TISSUE SARCOMAS: NEW PERSPECTIVES FOR DIAGNOSIS, PROGNOSIS AND PREDICTION OF TREATMENT EFFICACY IN RARE TUMORS | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-POC-2023-12378113 | A composite assay for HER2-positive early-stage breast cancer management | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-POC-2023-12377696 | Innovative drug delivery nanophotonic platform for implementation of sarcomas therapy (DEEPLY) | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377469 | Microbiota: its role in chronic inflammation, IBD and risk of colorectal cancer. Evaluation of a predictive prognostic model with therapeutic implications. | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12378239 | Radio-immunotherapy of solid tumors | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12377022 | Does prehabilitation be able to favorably impact on the pathway of head and neck cancer patients, candidate to surgery or chemoradiotherapy as primary treatment? A prospective clinical trial | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12378361 | Biomarker identification to guide therapeutic strategy in locally advanced rectal cancer | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12377293 | Rare breast cancer subtypes: towards a better understanding of the biology to improve clinical management | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377570 | Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-TR1-2023-12378400 | UNDERSTANDING THE RAREST GYNECOLOGICAL CANCERS: A MULTI -OMICS PLATFORM FOR IMPROVED PATIENTS MANAGEMENT (ROAR) | Istituto nazionale tumori Fondazione Giovanni Pascale |
| PNRR-MCNT2-2023-12377963 | KEAPness: a transcriptional framework for the molecular diagnosis of immunotherapy response in lung cancer with a tumor-agnostic potential | Istituto nazionale tumori Fondazione Giovanni Pascale |